Xenon Pharmaceuticals (XENE) Other Non-Current Assets (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 10 years of Other Non-Current Assets data on file, last reported at $8.3 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $8.3 million, up 3.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.3 million (up 3.13% YoY), and the FY2025 annual result was $7.2 million, down 4.6% from the prior year.
• Other Non-Current Assets rose to $8.3 million in Q1 2026 per XENE's latest filing, from $7.2 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $9.2 million in Q2 2025 and troughed at $7.1 million in Q3 2025.
• A 5-year average of $7.7 million and a median of $7.5 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets retreated 8.2% in 2024, then advanced 23.89% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $7.8 million in 2022, then declined by 4.58% to $7.4 million in 2023, then increased by 1.35% to $7.5 million in 2024, then fell by 4.6% to $7.2 million in 2025, then climbed by 16.14% to $8.3 million in 2026.
• Business Quant data shows XENE's Other Non-Current Assets at $8.3 million in Q1 2026, $7.2 million in Q4 2025, and $7.1 million in Q3 2025.